In Vivo Synergy Between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HTC-116 Xenografts (IMAGE)

Oncolytics Biotech Inc.

In Vivo Synergy Between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HTC-116 Xenografts

Caption

Poster by Dr. Maureen E. Lane et al. of Cornell University, N.Y., titled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts." Dr. Lane and her team found that treatment of human colon cancer cell lines with the combination of Reolysin and gemcitabine resulted in both in vitro and in vivo synergy. There was no toxicity associated with the combined treatment. Tumors treated with the combination were significantly smaller (by area and weight) than tumors in control groups or tumors treated with either agent alone. The researchers concluded that the synergistic combination of Reolysin and gemcitabine is a promising therapeutic regimen for study in clinical trials. Dr. Lane presented her findings at the American Association for Cancer Research Annual Meeting in Los Angeles, Calif. The meeting runs from April 14-18, 2007.

Credit

Dr. Maureen E. Lane and Oncolytics Biotech

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.